The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Development and characterization of novel erythropoiesis stimulating protein (NESP)
Open accessAbstract
Studies on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of the molecule and its serum half-life and in vivo biological activity, but an inverse relationship with its receptor-binding affinity. These observations led to the hypothesis that increasing the carbohydrate content, beyond that found naturally, would lead to a molecule with enhanced biological activity. Hyperglycosylated recombinant human EPO (rHuEPO) analogues were developed to test this hypothesis. Darbepoetin alfa (novel erythropoiesis stimulating protein, NESP, ARANESP, Amgen Inc, Thousand Oaks, CA), which was engineered to contain 5 N-linked carbohydrate chains (two more than rHuEPO), has been evaluated in preclinical animal studies. Due to its increased sialic acid-containing carbohydrate content, NESP is biochemically distinct from rHuEPO, having an increased molecular weight and greater negative charge. Compared with rHuEPO, it has an approximate 3-fold longer serum half-life, greater in vivo potency, and can be administered less frequently to obtain the same biological response. NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 2,005
Self-citationWinearls, C., Pippard, M., Downing, M., Oliver, D., Reid, C., & Mary Cotes, P. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Purification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citationExpression cloning of the murine erythropoietin receptor
D'Andrea, A. D., Lodish, H. F., & Wong, G. G. (1989) · Cell · doi:10.1016/0092-8674(89)90965-3 · Cited by 738
Efficiency of signalling through cytokine receptors depends critically on receptor orientation
Syed, R. S., Reid, S. W., Li, C., Cheetham, J. C., Aoki, K. H., Liu, B., Zhan, H., Osslund, T. D., Chirino, A. J., Zhang, J., et al. (1998) · Nature · doi:10.1038/26773 · Cited by 551
Self-citationSasaki, H., Bothner, B., Dell, A., & Fukuda, M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45317-3 · Cited by 484
Skehel, J. J., Stevens, D. J., Daniels, R. S., Douglas, A. R., Knossow, M., Wilson, I. A., & Wiley, D. C. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.6.1779 · Cited by 444
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Erythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Optimal and consistent protein glycosylation in mammalian cell culture
Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669
Glycoprotein Synthesis: An Update
Gamblin, D. P., Scanlan, E. M., & Davis, B. G. (2009) · Chemical Reviews · doi:10.1021/cr078291i · Cited by 596
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Enhancement of therapeutic protein in vivo activities through glycoengineering
Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt799 · Cited by 510
Self-citationVansteenkiste, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1211 · Cited by 477
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H., & Grau, R. (2011) · Nature Biotechnology · doi:10.1038/nbt.1839 · Cited by 473
Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins
Sinclair, A. M., & Elliott, S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20319 · Cited by 461
Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00006-7 · Cited by 421
Self-citationMolecular Biology of Erythropoietin
JELKMANN, W. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.649 · Cited by 383
Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
Diao, L., & Meibohm, B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0079-0 · Cited by 369
Erythropoietin after a century of research: younger than ever
Jelkmann, W. (2007) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00818.x · Cited by 367
Acute-on-chronic liver failure: terminology, mechanisms and management
Sarin, S. K., & Choudhury, A. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.219 · Cited by 342
Design and Chemical Synthesis of a Homogeneous Polymer-Modified Erythropoiesis Protein
Kochendoerfer, G. G., Chen, S.-Y., Mao, F., Cressman, S., Traviglia, S., Shao, H., Hunter, C. L., Low, D. W., Cagle, E. N., Carnevali, M., et al. (2003) · Science · doi:10.1126/science.1079085 · Cited by 312
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Washburn, N., Schwab, I., Ortiz, D., Bhatnagar, N., Lansing, J. C., Medeiros, A., Tyler, S., Mekala, D., Cochran, E., Sarvaiya, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422481112 · Cited by 225
Mechanisms of disease: The human N-glycome
Lauc, G., Pezer, M., Rudan, I., & Campbell, H. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.10.016 · Cited by 184
RNA interference of sialidase improves glycoprotein sialic acid content consistency
Ngantung, F. A., Miller, P. G., Brushett, F. R., Tang, G. L., & Wang, D. I. C. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20997 · Cited by 97
Glycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Thahsin, N., Khan, K. I., Sarwar, A. N. M. R., Sakib, M. N., & Rahman, M. S. (2025) · Computational and Structural Biotechnology Reports · doi:10.1016/j.csbr.2024.100029 · Cited by 2
Metadata
- Authors
- Egrie, J. C., & Browne, J. K.
- Venue
- British Journal of Cancer
- Published
- 2001
- Volume
- 84
- Issue
- s1
- Pages
- 3-10
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2145908121
- Cited by
- 510
- References
- 41
- FWCI
- 16.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.